HIV-1-infection, Inflammation, Sleep Deprivation
Conditions
Keywords
adenosine
Brief summary
People living with HIV (PLWH) often have poor sleep, which may put them at a higher risk for many chronic diseases, including cardiovascular disease. One of the mechanisms by which this may occur is via chronic inflammation and endothelial dysfunction. Adenosine plays an important role in sleep homeostasis, with levels increasing in the CSF in response to sleep deprivation and falling with sleep. Peripherally, adenosine, via its signaling pathway, plays an important role in immunoregulation by suppressing the inflammatory response. PLWH, even on antiretroviral therapy, have suppressed peripheral adenosine levels which are predictive of adverse cardiovascular outcomes. The hypothesis underlying this study is that acute sleep deprivation in PLWH does not result in a compensatory increase in extracellular adenosine and its signaling peripherally, and this failure to appropriately compensate, leads to an increase in systemic inflammation and endothelial dysfunction.
Detailed description
People living with HIV infection (PLWH) are known to be at higher risk of cardiovascular disease and also have a higher prevalence of poor sleep than people who do not have HIV infection. Understanding the underlying mechanisms for the elevated risk of cardiovascular disease in PLWH is important to developing novel strategies to mitigate this risk. Poor sleep has been postulated to mediate some of the elevated cardiovascular risk in PLWH given the high prevalence of poor sleep in PLWH and the epidemiologic association of poor sleep with adverse cardiovascular outcomes among people who do not have HIV infection. However, the mechanisms by which PLWH may be more sensitive to sleep loss from a cardiovascular standpoint are unclear. One potential explanation for any elevated sensitivity would be via alterations in the adenosine signaling pathway. Changes in extracellular adenosine levels in the brain and central nervous system play an important homeostatic role in sleep-wake regulation. Sleep deprivation results in a rise in extracellular adenosine levels while sleep itself leads to a rapid decline in levels. Peripheral adenosine signaling is a central feature of immunoregulation, primarily through its effects on inflammatory cytokine expression and lymphocyte adenosine receptor expression. PLWH tend to have a suppressed level of peripheral adenosine signaling and this level of suppression predicts risk of cardiovascular disease. The purpose of this study is to explore the impact of acute sleep deprivation among PLWH on measures of inflammation and endothelial function and to assess the extent to which any changes may be explained by alterations in peripheral adenosine signaling. The study will enroll 40 PLWH, age 18-75, who have been on ART for greater than 48 weeks. Screening with questionnaires, actigraphy and polysomnography will eliminate individuals with underlying chronic sleep abnormalities. A prior night of polysomnography in the sleep lab will also habituate subjects to sleeping while monitored in the sleep lab. Participants will arrive in the sleep laboratory in the evening and be allowed to sleep for 8 hours timed to their usual sleep patterns. On waking, participants will provide a urine sample that will be assayed for adenosine and adenosine metabolites. Blood will be drawn to measure markers of inflammation as well as markers of activation of the peripheral adenosine signaling system. Endothelial function will be assessed using flow mediated dilation. Participants will be kept awake for the subsequent 24 hours including the 8 hour normal sleep period. On the second morning, subjects will again provide urine and blood samples for the same bioassays described above and then undergo repeat assessment of endothelial function.
Interventions
Eight hour opportunity for sleep followed by 24 hours of sleep deprivation.
Sponsors
Study design
Masking description
Technicians processing biospecimens will be blinded to whether samples were collected on Day 1 or Day 2. Similarly, the assessor of brachial artery reactivity measurements will be blinded to whether ultrasound images were collected on Day 1 or Day 2.
Intervention model description
All participants will undergo one night of normal sleep (Night 1) followed by a subsequent night (Night 2) of sleep deprivation. Outcomes will be assessed the morning (Day 1 and Day 2) after each condition.
Eligibility
Inclusion criteria
* HIV positive * On continuous anti-retroviral therapy regimen for at least 48 weeks * CD4+ cell count greater than or equal to 200 cells/mm\^3
Exclusion criteria
* Irregular or insufficient habitual sleep patterns * Severe advanced or delayed sleep phase * Primary sleep disorder * Autoimmune disorder * Use of immunosuppressant medications * Use of medications impacting adenosine pathway * Heavy caffeine use * Active alcohol or drug abuse * Elevated risk of adverse health effects from sleep deprivation (e.g., bipolar disorder, epilepsy, or suicidal ideation in the past 6 months) * Pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Soluble CD14 | Baseline sleep replete state and after 24 hours of sleep deprivation | Plasma concentration of soluble CD14 |
| IL6 | Baseline sleep replete state and after 24 hours of sleep deprivation | Plasma concentration of interleukin-6 |
| Soluble CD163 | Baseline sleep replete state and after 24 hours of sleep deprivation | Plasma concentration of soluble CD163 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Monocyte Expression of IL6 | Baseline sleep replete state and after 24 hours of sleep deprivation | Percentage of circulating CD14+ peripheral blood mononuclear cells expressing interleukin-6 |
| Flow Mediated Brachial Artery Dilation | Baseline sleep replete state and after 24 hours of sleep deprivation | Percent change was calculated by measuring the brachial artery diameter at baseline and then the percent dilation from this baseline after release of occlusion at each time point. |
| Monocyte Expression of TNF-alpha | Baseline sleep replete state and after 24 hours of sleep deprivation | Percentage of circulating CD14+ peripheral blood mononuclear cells expressing tumor necrosis factor-alpha |
| CD4+ T-cell Expression of HLA-DR and CD38 | Baseline sleep replete state and after 24 hours of sleep deprivation | Percentage of CD3+ CD4+ T-lymphocytes co-expressing HLA-DR and CD38 |
| CD8+ T-cell Expression of HLA-DR and CD38 | Baseline sleep replete state and after 24 hours of sleep deprivation | Percentage of CD3+ CD8+ T-lymphocytes co-expressing HLA-DR and CD38 |
Other
| Measure | Time frame | Description |
|---|---|---|
| Urine 3'5'-cAMP | Baseline sleep replete state and after 24 hours of sleep deprivation | Urine 3'5'-cyclic adenosine monophosphate concentration normalized to creatinine |
| CD8+ T-cell Expression of CD39 and/or CD73 | Baseline sleep replete state and after 24 hours of sleep deprivation | Percentage of CD3+ CD8+ T-lymphocytes expressing CD39 and/or CD73 |
| Plasma Inosine | Baseline sleep replete state and after 24 hours of sleep deprivation | Plasma inosine concentration |
| Plasma Adenosine | Baseline sleep replete state and after 24 hours of sleep deprivation | Plasma adenosine concentration |
| CD4+ T-cell Expression of CD39 and/or CD73 | Baseline sleep replete state and after 24 hours of sleep deprivation | Percentage of CD3+ CD4+ T-lymphocytes expressing CD39 and/or CD73 |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Baseline (Sleep Repletion) Followed by Sleep Deprivation An 8 hour opportunity for sleep followed by outcome assessment the next morning and then 24 hour sleep deprivation followed by repeat outcome assessment. | 20 |
| Total | 20 |
Baseline characteristics
| Characteristic | Baseline (Sleep Repletion) Followed by Sleep Deprivation |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 5 Participants |
| Age, Categorical Between 18 and 65 years | 15 Participants |
| Age, Continuous | 61.1 years STANDARD_DEVIATION 9.7 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 20 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 1 Participants |
| Race (NIH/OMB) Black or African American | 7 Participants |
| Race (NIH/OMB) More than one race | 2 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 10 Participants |
| Region of Enrollment United States | 20 participants |
| Sex: Female, Male Female | 5 Participants |
| Sex: Female, Male Male | 15 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 20 |
| other Total, other adverse events | 1 / 20 |
| serious Total, serious adverse events | 0 / 20 |
Outcome results
IL6
Plasma concentration of interleukin-6
Time frame: Baseline sleep replete state and after 24 hours of sleep deprivation
Population: All 20 participants who completed the protocol and whose blood sample met quality control for the assay performed.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Baseline (Sleep Replete State) Followed by 24 Hours of Sleep Deprivation | IL6 | Baseline (Sleep repletion) | 4.46 pg/mL | Standard Deviation 2.06 |
| Baseline (Sleep Replete State) Followed by 24 Hours of Sleep Deprivation | IL6 | After sleep deprivation | 4.27 pg/mL | Standard Deviation 1.14 |
Soluble CD14
Plasma concentration of soluble CD14
Time frame: Baseline sleep replete state and after 24 hours of sleep deprivation
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Baseline (Sleep Replete State) Followed by 24 Hours of Sleep Deprivation | Soluble CD14 | Baseline (Sleep repletion) | 1290 ng/mL | Standard Deviation 405 |
| Baseline (Sleep Replete State) Followed by 24 Hours of Sleep Deprivation | Soluble CD14 | After sleep deprivation | 1196 ng/mL | Standard Deviation 533 |
Soluble CD163
Plasma concentration of soluble CD163
Time frame: Baseline sleep replete state and after 24 hours of sleep deprivation
Population: All 20 participants who completed the protocol and whose blood sample met quality control for the assay performed.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Baseline (Sleep Replete State) Followed by 24 Hours of Sleep Deprivation | Soluble CD163 | Baseline (Sleep repletion) | 359 ng/mL | Standard Deviation 231 |
| Baseline (Sleep Replete State) Followed by 24 Hours of Sleep Deprivation | Soluble CD163 | After sleep deprivation | 384 ng/mL | Standard Deviation 250 |
CD4+ T-cell Expression of HLA-DR and CD38
Percentage of CD3+ CD4+ T-lymphocytes co-expressing HLA-DR and CD38
Time frame: Baseline sleep replete state and after 24 hours of sleep deprivation
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Baseline (Sleep Replete State) Followed by 24 Hours of Sleep Deprivation | CD4+ T-cell Expression of HLA-DR and CD38 | Baseline (Sleep repletion) | 8.14 % cells | Standard Deviation 9.09 |
| Baseline (Sleep Replete State) Followed by 24 Hours of Sleep Deprivation | CD4+ T-cell Expression of HLA-DR and CD38 | After sleep deprivation | 8.39 % cells | Standard Deviation 9.01 |
CD8+ T-cell Expression of HLA-DR and CD38
Percentage of CD3+ CD8+ T-lymphocytes co-expressing HLA-DR and CD38
Time frame: Baseline sleep replete state and after 24 hours of sleep deprivation
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Baseline (Sleep Replete State) Followed by 24 Hours of Sleep Deprivation | CD8+ T-cell Expression of HLA-DR and CD38 | Baseline (Sleep repletion) | 12.30 % cells | Standard Deviation 10.74 |
| Baseline (Sleep Replete State) Followed by 24 Hours of Sleep Deprivation | CD8+ T-cell Expression of HLA-DR and CD38 | After sleep deprivation | 13.17 % cells | Standard Deviation 11.06 |
Flow Mediated Brachial Artery Dilation
Percent change was calculated by measuring the brachial artery diameter at baseline and then the percent dilation from this baseline after release of occlusion at each time point.
Time frame: Baseline sleep replete state and after 24 hours of sleep deprivation
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Baseline (Sleep Replete State) Followed by 24 Hours of Sleep Deprivation | Flow Mediated Brachial Artery Dilation | Baseline (Sleep repletion) | 6.13 % change | Standard Deviation 2.68 |
| Baseline (Sleep Replete State) Followed by 24 Hours of Sleep Deprivation | Flow Mediated Brachial Artery Dilation | After sleep deprivation | 4.42 % change | Standard Deviation 3.22 |
Monocyte Expression of IL6
Percentage of circulating CD14+ peripheral blood mononuclear cells expressing interleukin-6
Time frame: Baseline sleep replete state and after 24 hours of sleep deprivation
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Baseline (Sleep Replete State) Followed by 24 Hours of Sleep Deprivation | Monocyte Expression of IL6 | Baseline (Sleep repletion) | 84.6 % cells | Standard Deviation 13.6 |
| Baseline (Sleep Replete State) Followed by 24 Hours of Sleep Deprivation | Monocyte Expression of IL6 | After sleep deprivation | 89.1 % cells | Standard Deviation 8.3 |
Monocyte Expression of TNF-alpha
Percentage of circulating CD14+ peripheral blood mononuclear cells expressing tumor necrosis factor-alpha
Time frame: Baseline sleep replete state and after 24 hours of sleep deprivation
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Baseline (Sleep Replete State) Followed by 24 Hours of Sleep Deprivation | Monocyte Expression of TNF-alpha | Baseline (Sleep repletion) | 52.0 % cells | Standard Deviation 37.4 |
| Baseline (Sleep Replete State) Followed by 24 Hours of Sleep Deprivation | Monocyte Expression of TNF-alpha | After sleep deprivation | 64.1 % cells | Standard Deviation 32.4 |
CD4+ T-cell Expression of CD39 and/or CD73
Percentage of CD3+ CD4+ T-lymphocytes expressing CD39 and/or CD73
Time frame: Baseline sleep replete state and after 24 hours of sleep deprivation
CD8+ T-cell Expression of CD39 and/or CD73
Percentage of CD3+ CD8+ T-lymphocytes expressing CD39 and/or CD73
Time frame: Baseline sleep replete state and after 24 hours of sleep deprivation
Plasma Adenosine
Plasma adenosine concentration
Time frame: Baseline sleep replete state and after 24 hours of sleep deprivation
Plasma Inosine
Plasma inosine concentration
Time frame: Baseline sleep replete state and after 24 hours of sleep deprivation
Urine 3'5'-cAMP
Urine 3'5'-cyclic adenosine monophosphate concentration normalized to creatinine
Time frame: Baseline sleep replete state and after 24 hours of sleep deprivation